Resources

The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (September 2019)

The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here

Presentations from the 2019 MS Summit

View Presentations here

The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (June 2019)

The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here

The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (March 2019)

The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here

The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (April 2017)

The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people with MS in the United States. Download here

The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (March 2017)

The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people with MS in the United States. Download here

MS Coalition Brochure (January 2012)

The Multiple Sclerosis Coalition (MSC) was founded in 2005 by three independent multiple sclerosis (MS) organizations in an effort to work together to benefit individuals with MS. Since that time, the MSC has grown to nine member organizations, all of whom provide critical MS programs and services.    Download here

Follow us on Twitter

TwitterFollow

MS Coalition
Retweet on TwitterMS Coalition Retweeted
MSIntFederationMS Int'l Federation@MSIntFederation·
13 Jan

Today we have published updated global advice for people with MS on the COVID-19 mRNA vaccines (Pfizer-BioNTech & Moderna). This advice has been developed by MS clinicians and research experts from across the global MS movement. #MSCOVID19

Find out more➡️ http://www.msif.org/covid19

Reply on Twitter 1349348256061546496Retweet on Twitter 134934825606154649612Like on Twitter 134934825606154649618Twitter 1349348256061546496
Retweet on TwitterMS Coalition Retweeted
MS_FocusMS Focus: The Multiple Sclerosis Foundation@MS_Focus·
10 Jan

Participate in this interactive demonstration of dance therapy for MS. It's adapted for people of all abilities. Join us for this free conference on Friday, Jan 15 at 2:00 p.m. Eastern. Pre-register at https://buff.ly/2XvgvYZ

Reply on Twitter 1348386455127810048Retweet on Twitter 13483864551278100483Like on Twitter 13483864551278100482Twitter 1348386455127810048
Retweet on TwitterMS Coalition Retweeted
MSHealthCentralMSHealthCentral@MSHealthCentral·
6 Jan

A Relative Afferent Pupillary Defect (RAPD) or Marcus Gunn pupil is a sign of damage to the optic nerve, which can be a symptom multiple sclerosis (MS).

http://ow.ly/jdTY50CwGQt

Reply on Twitter 1346817567269281794Retweet on Twitter 13468175672692817941Like on Twitter 1346817567269281794Twitter 1346817567269281794
Load More...